Beam Therapeutics Named to Boston Globe’s Top Places to Work List for 2022
02. Dezember 2022 14:00 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Announces FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for BEAM-201
02. Dezember 2022 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the...
Beam Therapeutics to Participate in the BofA Securities 2022 Virtual Biotech SMID Cap Conference
30. November 2022 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Enrolls First Patient in BEACON Clinical Trial of BEAM-101 Base Editing Therapy Candidate for the Treatment of Sickle Cell Disease
14. November 2022 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics to Participate in Upcoming Investor Conferences
09. November 2022 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results
07. November 2022 06:30 ET
|
Beam Therapeutics
Patient Recruitment Underway in BEACON Clinical Trial of BEAM-101 for Treatment of Sickle Cell Disease as Part of Wave 1 Strategy Execution IND-enabling Studies Underway for BEAM-301 for Treatment of...
Beam Therapeutics to Present New Preclinical Data Highlighting Non-Genotoxic Conditioning Regimens for Patients with Sickle Cell Disease Ahead of Autologous Transplant at the 64th ASH Annual Meeting
03. November 2022 09:01 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Presents First In Vivo Data Demonstrating Potential of Multiplex Base Editing Approach to Target Disease Drivers of Chronic Hepatitis B Infection
19. September 2022 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced new...
Beam Therapeutics to Participate at the Wells Fargo 2022 Healthcare Conference
01. September 2022 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Announces Pipeline and Business Highlights and Reports Second Quarter 2022 Financial Results
09. August 2022 06:30 ET
|
Beam Therapeutics
Patient Enrollment into BEACON Phase 1/2 Trial of BEAM-101 On-track for Second Half of 2022 BEAM-201 IND Submitted to FDA; Currently on Clinical Hold BEAM-102 IND Submission and BEAM-301...